Anacor Pharmaceuticals said that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) seeking approval of crisaborole topical ointment, 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults. The Prescription Drug User Fee Act (PDUFA) goal date for the completion of the FDA’s review is January 7, 2017. “We believe th...